Immune protection against trypanosoma cruzi infection: efficacy of two new generation adjuvants to formulate a subunit vaccine with trans-sialidase antigen

BONTEMPI, IVAN; CABRERA, GABRIEL; VICCO, MIGUEL; BERTONA, DAIANA; VILLAR, SILVINA; GONZALEZ, FLORENCIA; PUJATO, NAZARENA; NICASTRO, ALCIDES; PÉREZ, ANA; MARCIPAR, IVAN

Mar del Plata

Congreso; LIX Reunión Científica Anual de la Sociedad Argentina de Investigación Clínica, LXII Reunión Científica Anual de la Sociedad Argentina de Inmunología; 2014

Sociedad Argentina de Investigación Clínica y Sociedad Argentina de Inmunología

New generations adjuvants are able to enhance the efficacy of recombinant protein vaccines which are considered to be the safer ones but which typically promotes weak Immune responses. ISCOMATRIX (IMX) is a particularly special adjuvant as it has shown to be effective and safe in human clinical trials of vaccines designed to control intracellular infections by promoting a CTL response.Therefore, as a first step we assessed the immune protection achieved using this adjuvant to formulate mutant inactive transialidase (mTS), previously proven to be highly protective against T. cruzi infection. Mice were immunized with mTS-IMX, mTS-IFA (IFA, incomplete Freund adjuvant), mTS (without adjuvant), IMX (without antigen) and PBS. mTS-IMX showed a TS-specific IgG response with titers >106 and high avidity, an increased IgG2a/IgG1 ratio, significant delayed-type hypersensitivity (DTH) reactivity and a balanced IFN-g and IL-10 production, compared to mice immunized with mTS or IMX in PBS or vehicle (PBS) (p